Shares of Allakos Inc (NASDAQ:ALLK) hit a new 52-week high during trading on Wednesday . The company traded as high as $51.75 and last traded at $48.78, with a volume of 693 shares traded. The stock had previously closed at $47.13.
ALLK has been the topic of a number of analyst reports. Zacks Investment Research raised Allakos from a “hold” rating to a “buy” rating and set a $38.00 price target on the stock in a research report on Monday, October 15th. Goldman Sachs Group initiated coverage on Allakos in a research report on Monday, August 13th. They issued a “neutral” rating and a $31.00 price target on the stock. William Blair initiated coverage on Allakos in a research report on Monday, August 13th. They issued an “outperform” rating on the stock. Finally, Jefferies Financial Group initiated coverage on Allakos in a research report on Monday, August 13th. They issued a “buy” rating and a $53.00 price target on the stock.
Allakos (NASDAQ:ALLK) last announced its quarterly earnings data on Wednesday, August 29th. The company reported ($4.17) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.27) by ($3.90). Equities analysts anticipate that Allakos Inc will post -1.07 EPS for the current year.
About Allakos (NASDAQ:ALLK)
Allakos Inc, a clinical stage biopharmaceutical company, focuses on developing therapeutic antibodies targeting allergic, inflammatory, and proliferative diseases. The company is developing AK002 for the treatment of eosinophilic gastritis and eosinophilic gastroenteritis, urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis.
Recommended Story: What is a Fiduciary?
Receive News & Ratings for Allakos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allakos and related companies with MarketBeat.com's FREE daily email newsletter.